DE102006015341A1 - Behandlung von multipler Sklerose und/oder rheumatoider Arthritis - Google Patents

Behandlung von multipler Sklerose und/oder rheumatoider Arthritis Download PDF

Info

Publication number
DE102006015341A1
DE102006015341A1 DE102006015341A DE102006015341A DE102006015341A1 DE 102006015341 A1 DE102006015341 A1 DE 102006015341A1 DE 102006015341 A DE102006015341 A DE 102006015341A DE 102006015341 A DE102006015341 A DE 102006015341A DE 102006015341 A1 DE102006015341 A1 DE 102006015341A1
Authority
DE
Germany
Prior art keywords
antibody
treatment
ccr2
monocytes
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102006015341A
Other languages
German (de)
English (en)
Inventor
Marco Prinz
Wolfgang BRÜCK
Alexander Mildner
Matthias Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georg August Universitaet Goettingen
Universitaet Regensburg
Universitaetsmedizin Goettingen Georg August Universitaet
Original Assignee
Georg August Universitaet Goettingen
Universitaet Regensburg
Universitaetsmedizin Goettingen Georg August Universitaet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Universitaet Goettingen, Universitaet Regensburg, Universitaetsmedizin Goettingen Georg August Universitaet filed Critical Georg August Universitaet Goettingen
Priority to DE102006015341A priority Critical patent/DE102006015341A1/de
Priority to AU2007236269A priority patent/AU2007236269B2/en
Priority to JP2009503466A priority patent/JP2009532399A/ja
Priority to EP07723870.7A priority patent/EP2004692B1/de
Priority to CA2648330A priority patent/CA2648330C/en
Priority to US12/295,718 priority patent/US9068002B2/en
Priority to PCT/EP2007/002929 priority patent/WO2007115713A1/de
Priority to CNA2007800203076A priority patent/CN101466735A/zh
Priority to EP12165439A priority patent/EP2481757A1/de
Publication of DE102006015341A1 publication Critical patent/DE102006015341A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE102006015341A 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis Withdrawn DE102006015341A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE102006015341A DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
AU2007236269A AU2007236269B2 (en) 2006-04-03 2007-04-02 Treatment of multiple sclerosis and/or rheumatoid arthritis
JP2009503466A JP2009532399A (ja) 2006-04-03 2007-04-02 多発性硬化症および／または関節リウマチの処置
EP07723870.7A EP2004692B1 (de) 2006-04-03 2007-04-02 Behandlung von multipler sklerose und/oder rheumatoider arthritis mittels anti-ccr2 antikörpern
CA2648330A CA2648330C (en) 2006-04-03 2007-04-02 Anti-ccr2 antibody depletes monocytes to treat multiple sclerosis and rheumatoid arthritis
US12/295,718 US9068002B2 (en) 2006-04-03 2007-04-02 Treatment of multiple sclerosis and/or rheumatoid arthritis
PCT/EP2007/002929 WO2007115713A1 (de) 2006-04-03 2007-04-02 Behandlung von multipler sklerose und/oder rheumatoider arthritis
CNA2007800203076A CN101466735A (zh) 2006-04-03 2007-04-02 多发性硬化和/或类风湿性关节炎的治疗
EP12165439A EP2481757A1 (de) 2006-04-03 2007-04-02 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006015341A DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis

Publications (1)

Publication Number Publication Date
DE102006015341A1 true DE102006015341A1 (de) 2007-10-04

Family

ID=38226352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102006015341A Withdrawn DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis

Country Status (8)

Country Link
US (1) US9068002B2 (https=)
EP (2) EP2004692B1 (https=)
JP (1) JP2009532399A (https=)
CN (1) CN101466735A (https=)
AU (1) AU2007236269B2 (https=)
CA (1) CA2648330C (https=)
DE (1) DE102006015341A1 (https=)
WO (1) WO2007115713A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276991C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
CN110709422B (zh) * 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
WO2020232127A1 (en) * 2019-05-13 2020-11-19 The Research Foundation For The State University Of New York Compositions and methods to block and bind ccr2 to modulate cellular function
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
MX2024004447A (es) 2021-10-27 2024-05-08 Granite Bio Ag Anticuerpos dirigidos a ccr2.
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
JP4398620B2 (ja) * 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
SE0002045D0 (sv) 2000-05-31 2000-05-31 Sahltech Ab New use
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
MXPA06000176A (es) 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.

Also Published As

Publication number Publication date
US20090311273A1 (en) 2009-12-17
CA2648330A1 (en) 2007-10-18
JP2009532399A (ja) 2009-09-10
CA2648330C (en) 2015-11-24
CN101466735A (zh) 2009-06-24
EP2004692B1 (de) 2013-07-24
US9068002B2 (en) 2015-06-30
EP2481757A1 (de) 2012-08-01
WO2007115713A1 (de) 2007-10-18
EP2004692A1 (de) 2008-12-24
AU2007236269B2 (en) 2012-09-20
AU2007236269A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE60035057T2 (de) CD40 Antagonist zur Behandlung von Psoriasis
Chu et al. Interferon‐γ regulates susceptibility to collagen‐induced arthritis through suppression of interleukin‐17
DE3853636T3 (de) Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
DE60106394T2 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
DE69032662T2 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE69229275T2 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
DE69329558T2 (de) Verfahren zur Behandlung von Multiplesklerose
DE60217698T2 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE60127237T2 (de) Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie
EP2004692B1 (de) Behandlung von multipler sklerose und/oder rheumatoider arthritis mittels anti-ccr2 antikörpern
EP1600460A1 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE60224200T2 (de) Assayverfahren für alzheimer-krankheit
DE68908431T2 (de) Methode zur Verminderung der Immunglobulin-E-Reaktion.
DE69837322T2 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE69825473T2 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
DE112012000439T5 (de) Stammzellfaktor-Inhibitor
EP0340604B1 (de) Monoklonaler Antikörper und seine Verwendung
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
DE69232295T2 (de) Verfahren zur Verbesserung der Toleranz für Allotransplantaten und Xenotransplantaten durch Verabreichung eines LFA-3- oder CD2-Bindungsproteins
DE69818106T2 (de) Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
DE69413009T2 (de) Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
DE112018002302T5 (de) Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung

Legal Events

Date Code Title Description
R012 Request for examination validly filed

Effective date: 20130221

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20141101